ResearchSafe

NYT piece on China's longevity push, the science is shakier than the hype

Posted by weekendnate in Research & News - 2 points, 4 comments.

https://www.nytimes.com/2025/11/08/world/asia/china-aging-longevity-science.html

The NYT ran a piece on China's national longevity project, the "immortality islands," the grape seed pills, the whole spectacle. Worth a read because it lays out how much state money is flowing into this space, and how much of the actual science behind the marketed stuff is thin.

My take: the cultural angle is fun, but the bigger story is how uncritically a lot of the public is treating longevity research right now. GLP-1s get lumped in with grapeseed extract and some folk herb cocktail, and suddenly it's all "anti-aging." Real aging biology is moving, slowly, and most of the loud claims aren't where the real progress is. I want to see the actual trial data, not a TED talk.

What about you, do you think the longevity space is getting better or worse at separating signal from noise right now?

Comments

  • grinder265: Ngl the GLP-1 lumping is the part that bugs me most. Those are mechanism-driven drugs with RCTs coming out the wazoo. Grape seed extract and some TCM compound some VC is funding because of a WeChat article is a completely different evidence tier and acting like they are equivalent does a disservice to both. The noise problem also makes it harder for legit stuff to get proper scrutiny IMO. When everything is overhyped, the actual dose-response data and safety signals just get drowned out. Are y
  • weekendnate: Yeah, rapamycin especially. I've been tracking who actually pulls dose-response data versus who just posts a flashy before/after. The senolytic crowd is a little better about it since Daschner and others keep pushing for intermittent dosing data, but rapamycin forums are full of people running daily protocols with zero bloodwork and calling it biohacking. That part drives me nuts. Also agree on the drowning out effect. When my patients ask about longevity stuff, half the time they mean Ozempic
  • patient_protocol: Yeah I see it with rapamycin especially, and it's a shame because the mTOR data is genuinely interesting but every other person on forums is talking about it like it's a done deal for longevity when we barely have solid dosing data in healthy folks. Senolytics might be worse honestly, dasatinib plus quercetin gets thrown around with this confidence that just isn't earned yet, and the "senolytic" label itself does a lot of heavy lifting in marketing. Course that doesn't mean it's all hype, just
  • weekendnate: Rapamycin is a perfect example honestly, the mechanistic stuff on mTOR is genuinely compelling but the dosing question in healthy people is basically unanswered. People are running wild with weekly protocols based on transplant data, and that's a stretch. Senolytics I agree are even worse, the "clears zombie cells" framing does so much work in those forum posts and the human data is still tiny. I'd rather see more boring readouts from actual trials than another "stack" post.

Community discussion - research and educational context only. Not medical advice.